Biocartis launches KRAS diagnostic

Biocartis Group N.V. (Euronext:BCART) launched the Idylla KRAS Mutation Test to detect clinically relevant mutations in colorectal cancer (CRC). The company said the in vitro diagnostic received CE-IVD marking.

Biocartis said the molecular diagnostic detects 21 mutations in the KRAS oncogene from tumor samples in about two hours. ...